Alkermes plc. Increase Decrease In Operating Lease Liability
Alkermes plc. (ALKS) reported Increase Decrease In Operating Lease Liability of -$7.59 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-10-24.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2024-10-24
- Alkermes plc. increase decrease in operating lease liability for the quarter ending 2024-09-30 was -$2.54M.
- Alkermes plc. increase decrease in operating lease liability for the quarter ending 2024-06-30 was -$2.53M.
- Alkermes plc. increase decrease in operating lease liability for the quarter ending 2024-03-31 was -$2.52M.
- Alkermes plc. increase decrease in operating lease liability for the quarter ending 2023-09-30 was -$4.10M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month |
|---|---|---|---|
| 2024-09-30 | -$2.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-24 | -$5.08M derived: sum of 2 quarters · filed 2024-10-24 | -$7.59M 10-Q · filed 2024-10-24 |
| 2024-06-30 | -$2.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-24 | -$5.05M 10-Q · filed 2024-07-24 | |
| 2024-03-31 | -$2.52M 10-Q · filed 2024-05-01 | ||
| 2023-09-30 | -$4.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-24 | -$8.19M derived: sum of 2 quarters · filed 2024-10-24 | -$12.57M 10-Q · filed 2024-10-24 |
| 2023-06-30 | -$4.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-24 | -$8.47M 10-Q · filed 2024-07-24 | |
| 2023-03-31 | -$4.38M 10-Q · filed 2024-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |